Short answer
Tonix Pharmaceuticals Holding Corp. (TNXP) filed an 8-K current report with the SEC on October 2, 2026 reporting Item 8.01 (Other Events). DRL filed a Paragraph IV ANDA seeking generic TONMYA 2.8 mg, directly threatening Tonix’s branded-product exclusivity.
Tonix Pharmaceuticals Holding Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- DRL filed a Paragraph IV ANDA seeking generic TONMYA 2.8 mg, directly threatening Tonix’s branded-product exclusivity
- Challenge covers all four Orange Book patents: U.S. Patent Nos. 9636408, 9956188, 10117936 and 10864175
- Tonix has 45 days from October 1, 2026 to sue, potentially triggering a 30-month FDA approval stay
- Litigation could protect TONMYA sales or accelerate generic competition, with material revenue and legal-cost implications
- Outcome remains uncertain, including patent validity, enforceability and infringement findings
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tonix Pharmaceuticals Holding Corp. 8-K filings
Get the next TNXP 8-K as it lands
Follow TNXP for push alerts, or ask the research agent what this filing means.